MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Rhea-AI Summary

MiNK Therapeutics announced the acceptance of five abstracts at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, scheduled for November 8-12, 2022. These abstracts focus on clinical data for AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy targeting advanced solid tumors, viral ARDS, and refractory multiple myeloma. New therapeutic candidates, MiNK-215 and MiNK-413, are also highlighted, showcasing advancements in CAR-iNKT therapy. The meeting will feature presentations from several experts, emphasizing the company's commitment to innovative cancer treatments.

Positive

• Five abstracts accepted for presentation at SITC 37th Annual Meeting, indicating strong academic interest.
• Focus on AgenT-797 for advanced solid tumors and viral ARDS showcases potential for diverse applications.
• Introduction of new therapeutic candidates MiNK-215 and MiNK-413 expands the treatment pipeline.

Negative

• None.

• Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumors
  
• Clinical data of AgenT-797 in viral ARDS and refractory multiple myeloma
• New therapeutic candidates: 1) MiNK-215, an allo-FAP-CAR-iNKT; 2) MiNK-413, allo-armored-BCMA-CAR-iNKT
  

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the acceptance of five abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 37^th Annual Meeting, to be held November 8 – 12^th, 2022.

Presentation Details:

Abstract Title: Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma
Abstract number: 647
Presenting Author: Dr. David Einstein
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

Abstract Title: Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (viral ARDS) secondary to SARS-CoV-2 (COVID-19)
Abstract Number: 649
Presenting Author: Dr. Terese Hammond
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

Abstract Title: Development of an allogenic FAP-CAR-iNKT product to target tumor stroma and modulate the Tumor Microenvironment
Abstract Number: 358
Presenting Author: Xavier Michelet, PhD  
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

Abstract Title: MiNK-413: a Next generation armored allogenic BCMA-CAR-iNKT product
Abstract Number: 322
Presenting Author: Eleni Chantzoura, PhD
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

Abstract Title: agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment
Abstract Number: 372
Presenting Author: Sapana Kadel
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

FAQ

What are the key highlights from MiNK Therapeutics' recent press release?

MiNK Therapeutics has accepted five abstracts for presentation at the SITC 37th Annual Meeting, focusing on AgenT-797 for advanced solid tumors and viral ARDS, along with two new candidates, MiNK-215 and MiNK-413.

When is the SITC 37th Annual Meeting where MiNK Therapeutics will present?

The SITC 37th Annual Meeting is scheduled for November 8-12, 2022.

What is AgenT-797 and its significance?

AgenT-797 is a novel allogeneic iNKT cell therapy targeting advanced solid tumors and has shown potential in treating viral ARDS and multiple myeloma.

What are MiNK-215 and MiNK-413?

MiNK-215 is an allo-FAP-CAR-iNKT, and MiNK-413 is an allo-armored-BCMA-CAR-iNKT, both representing new therapeutic candidates in MiNK's pipeline.

Who is presenting the abstracts for MiNK Therapeutics at the SITC meeting?

The abstracts will be presented by Dr. David Einstein, Dr. Terese Hammond, and other experts.